Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…

Institute of Health Information and Statistics of the Czech Republic (further on “the Institute“) was established in 1960. The Institute is an organisational component of the State; its founder is the Ministry of Health.
The National Health Information System (further on “NHIS“) is defined in Act no. 372/2011Sb, On health services and conditions of their provision (Act on health services) in Section 70, paragraph 1 (the Act is valid since April. 2012).
Administration of NHIS is delegated by MH to the Institute in accordance with the basic purpose and objective of its activity that follows from the Statute of the Institute. The extent of the mandate of the Institute is defined in Section 72, paragraph 1, letters a) to d) and f) of Act no. 372/2011Sb, on health services.
In handling personal data in NHIS the Institute proceeds in accordance with Act no. 101/2000 Sb., On personal data protection, in wording of later regulations.
The Institute is a component of the State Statistical Service (on the basis of the competence act) and performs this activity according to Act no. 89/1995 Sb., On state statistical service, in wording of later regulations. It cooperates with organs of State Statistical Service, mainly with Czech Statistical Office, it secures connection between NHIS and individual health care providers and it cooperates with the operators of information systems of other organisations in and out of the health sector.
The Institute will continue to follow the principles of the European Statistics Code of Practice that represents the common summary of European standards designated for statistical organs and for the whole European statistical system with the aim to secure high quality and credibility of European data. These principles concern, among other things, professional independence, confidentiality protection, reliability of the data and their precision, timeliness, punctuality, accessibility, intelligibility, clarity, comparability and consistency.
The Institute cooperates with associations of hospitals, associations of physicians, professional medical societies, health insurance companies and other organisations, particularly on precise specification of the NHIS contents and on utilisation of the collected data.
On the international level of health statistics the Institute cooperates particularly with WHO, OECD, the UN, EUROSTAT and other organisations. The Institute is the official presenter of NHIS data for the Czech Republic.
Contact
Institute of health information and statistics of the Czech Republic
Palackého nám. 4 , P.O.BOX 60,
128 01 Praha
email: uzis@uzis.cz
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I…
You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets?…
Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the…
Dr. Heger, you were appointed as the Czech Minister of Health in July of 2010. What challenges did you see for the Czech healthcare system, and what has been your…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers.…
Ms. Hauser, you represent what is perhaps the last major generation of medical doctors in this country that left the medical field to join the pharmaceutical business. What do you…
Mr. Krejčí, can you please begin with a broad introduction to Ewopharma, for those of our readers who are unfamiliar with the company? Ewopharma is part of a large group…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr. Zörner, executive director of…
Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an association of Czech biotech companies that started its…
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has…
See our Cookie Privacy Policy Here